Clinical Trial and Real-World Evidence Around CAR T-cell Therapy in LBCL

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Why do some patients with follicular lymphoma experience benefit from axi-cel while others relapse or develop severe toxicities?

Two teams of lymphoma experts engage in a face-off competition, showcasing real-world updates, patient cases, and use of ASCT or CAR T-cell therapy.